Salem Al-Dosari, MohammedMohamed Ghorab, MostafaSulaiman Al-Said, MansourMohammed Nissan, Yassin2019-10-212019-10-2120131) Gopal M., Shenoy S., Doddamani L. S., J. Photochem. Photobiol. B, 72, 69–78 (2003). 2) Kim Y. H., Shin K. J., Lee T. G., Kim E., Lee M. S., Ryu S. H., Suh P. G., Biochem. Pharmacol., 69, 1333–1341 (2005). 3) Zhao Y. L., Chen Y. L., Chang F. S., Tzeng C. C., Eur. J. Med. Chem., 40, 792–797 (2005). 4) Wall M. E., Wani M. C., Cook C. E., Palmer K. H., McPhail A. T., Sims G. A., J. Am. Chem. Soc., 88, 3888–3890 (1966). 5) Ma Z. Z., Hano Y., Nomura T., Chen Y. J., Heterocycles, 46, 541–546 (1997). 6) Kobayash J., Cheng J., Nakamura H., Ohizumi Y., Hirata Y., Sasaki T., Ohta T., Nozoe S., Tetrahedron Lett., 29, 1177–1180 (1988). 7) Utsugi T., Aoyagi K., Asao T., Okazaki S., Aoyagi Y., Sano M., Wierzba K., Yamada Y., Jpn. J. Cancer Res., 88, 992–1002 (1997). 8) Jonckers T. H., van Miert S., Cimanga K., Bailly C., Colson P., De Pauw-Gillet M. C., van den Heuvel H., Claeys M., Lemière F., Esmans E. L., Rozenski J., Quirijnen L., Maes L., Dommisse R., Lemière G. L., Vlietinck A., Pieters L., J. Med. Chem., 45, 3497–3508 (2002). 9) Peczyńska-Czoch W., Pognan F., Kaczmarek L., Boratyński J., J. Med. Chem., 37, 3503–3510 (1994). 10) Drews J., Science, 287, 1960–1964 (2000). 11) Supuran C. T., Scozzafava A., Curr. Med. Chem. Immunol. Endocr. Metab. Agents, 1, 61–97 (2001). 12) Maren T. H., Annu. Rev. Pharmacol. Toxicol., 16, 309–327 (1976). 13) Boyd A. E. 3rd, Diabetes, 37, 847–850 (1988). 14) Thornber C. W., Chem. Soc. Rev., 8, 563–580 (1979). 15) Casini A., Scozzafava A., Mastrolorenzo A., Supuran L. T., Curr. Cancer Drug Targets, 2, 55–75 (2002). 16) Supuran C. T., Nat. Rev. Drug Discov., 7, 168–181 (2008). 17) Supuran C. T., Scozzafava A., Bioorg. Med. Chem., 15, 4336–4350 (2007). 18) Supuran C. T., Scozzafava A., Casini A., Med. Res. Rev., 23, 146– 189 (2003). 19) Knight S. D., Schmidt S. J., Smithkline beecham corporation, US Patent: US 8138347 (2008). 20) Ghorab M. M., Ragab F. A., Noaman E., Heiba H. I., El-Hossary E. M., Arzneimittelforschung, 57, 795–803 (2007). 21) Ghorab M. M., Ragab F. A., Noaman E., Heiba H. I., El-Hossary E. M., Arzneimittelforschung, 58, 35–41 (2008). 22) Hogle M. B., Shelar A. R., Kachare D. S., Salunkhe V. K., J. Indian Chem. Soc., 64, 314–316 (1987). 23) Zhong B., Al-Awar R. S., Shih C., Grimes J. H. Jr., Vieth M., Hamdouchi C., Tetrahedron Lett., 47, 2161–2164 (2006). 24) Weinstein I. B., Begemann M., Zhou P., Han E. K., Sgambato A., Doki Y., Arber N., Ciaparrone M., Yamamoto H., Clin. Cancer Res., 3, 2696–2702 (1997). 25) Weinstein I. B., Joe A. K., Nat. Clin. Pract. Oncol., 3, 448–457 (2006). 26) Jia S., Liu Z., Zhang S., Liu P., Zhang L., Lee S. H., Zhang J., Signoretti S., Loda M., Roberts T. M., Zhao J. J., Nature, 454, 776–779 (2008). 27) Wee S., Wiederschain D., Maira S. M., Loo A., Miller C., deBeaumont R., Stegmeier F., Yao Y. M., Lengauer C., Proc. Natl. Acad. Sci. U.S.A., 105, 13057–13062 (2008). 28) Crabbe T., Welham M. J., Ward S. G., Trends Biochem. Sci., 32, 450–456 (2007). 29) Kim D., Kim S., Koh H., Yoon S. O., Chung A. S., Cho K. S., Chung J., FASEB J., 15, 1953–1962 (2001). 30) Boller D., Schramm A., Doepfner K. T., Shalaby T., von Bueren A. O., Eggert A., Grotzer M. A., Arcaro A., Clin. Cancer Res., 14, 1172–1181 (2008). 31) Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R., J. Natl. Cancer Inst., 82, 1107–1112 (1990)https://doi.org/https://cutt.ly/ErX4U9FMSA Google ScholarBased on the reported anticancer activity of quinolines, a new series of 7-chloroquinoline derivatives bearing the biologically active benzenesulfonamide moiety 2–17 and 19–25 were synthesized starting with 4,7-dichloroquinolne 1. Compound 17 was the most active compound with IC50 value 64.41, 75.05 and 30.71 μm compared with Doxorubicin as reference drug with IC50 values 82.53, 88.32 and 73.72 μm on breast cancer cells, skin cancer cells and neuroblastoma, respectively. All the synthesized compounds were evaluated for their in vitro anticancer activity on breast cancer cells, skin cancer cells and neuroblastoma cells. Most of the synthesized compounds showed moderate activity. In order to suggest the mechanism of action for their cytotoxic activity, molecular docking for all synthesized compounds was done on the active site of phosphoinositide kinase (PI3K) and good results were obtained.enquniolinesulfonamideanticancer activityArticlehttps://doi.org/